BioArctic Stock

BioArctic Working Capital

The Working Capital of BioArctic (BIOA B.ST) as of Aug 12, 2026 is 1.97 B SEK. In the previous year, Working Capital was 1.33 B SEK — a change of 47.53% (higher).

Working Capital

1.97 BSEK

YoY

47.53%

Last updated:

Working Capital of BioArctic is 2026 1.97 B SEK. Working Capital of BioArctic was 2025 1.33 B SEK. It decreases by 47.53% higher compared to the previous year.
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Working Capital of BioArctic is 1.97 B SEK in 2026.

Working Capital of BioArctic changed from 1.33 B SEK to 1.97 B SEK, representing a 47.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital BioArctic since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's BioArctic historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — BioArctic

All Key Metrics — BioArctic